	US 11,918,572 B2
	Pharmaceutical compositions for treating pain
Brett Hale Davis, Salt Lake City, UT (US); Caleb Adrian Lade, Salt Lake City, UT (US); Sierra Nichelle Erickson, Salt Lake City, UT (US); and Susan Alice Wojtalewicz, Salt Lake City, UT (US)
Assigned to REBEL MEDICINE INC, Salt Lake City, UT (US)
Filed by REBEL MEDICINE INC, Salt Lake City, UT (US)
Filed on Jan. 27, 2023, as Appl. No. 18/160,874.
Claims priority of provisional application 63/267,256, filed on Jan. 28, 2022.
Prior Publication US 2023/0241048 A1, Aug. 3, 2023
Int. Cl. A61K 31/277 (2006.01); A61K 31/445 (2006.01); A61K 47/14 (2017.01); A61K 47/44 (2017.01); A61P 23/02 (2006.01)

CPC A61K 31/445 (2013.01) [A61K 47/14 (2013.01); A61K 47/44 (2013.01); A61P 23/02 (2018.01)]

5 Claims

1. An injectable pharmaceutical composition, comprising:

bupivacaine in a range of from about 3 wt % to about 7 wt % of the pharmaceutical composition;

medium-chain triglyceride oil in a range of from about 39.5 wt % to about 46.5 wt % of the pharmaceutical composition;

a castor oil in a range of from about 39.5 wt % to about 46.5 wt % of the pharmaceutical composition; and

tristearin in a range of from about 0.5 wt % to about 6 wt % of the pharmaceutical composition, wherein

the pharmaceutical composition is free of a rheological modifier and

a wt:wt ratio of the medium-chain triglyceride to castor oil is about 50:50.